JD Health: AI Crosses the Threshold from Tool to Business
Margins expand for ninth straight quarter as AI monetization and regulatory tailwinds take shape
6618.HK · Earnings Call · 2026-08-13
Financial Discipline Meets AI Ambition
JD Health delivered a first-half 2026 report that underscores its dual mantra: mature supply-chain leadership in pharmaceuticals and a carefully timed push to commercialize AI-powered healthcare. The headline numbers were strong—total revenue reached RMB 40.9 billion, non-IFRS operating income grew 40.3% year-over-year, and operating margin expanded by 1.5 percentage points to 8.5%, marking the ninth consecutive quarter of year-over-year margin improvement. As CFO Deng Hui put it, “our non-IFRS operating margin expanded by 1.5 percentage points to 8.5%, marking 9 consecutive quarters of the year-over-year growth.” — Deng Hui, CFO · 2026-08-13 The gross margin also ticked up 0.9 points to 26.1%, supported by procurement optimization and economies of scale. What mattered more than the absolute numbers was the narrative around AI. CEO Cao Dong, in response to a question about profitability drivers, reiterated that the company is confident in sustaining growth and aiming for a high single-digit operating margin over the long term. But the real inflection point lay in his remarks on AI: “AI cannot only reduce costs and improve efficiency it can also become a stand-alone business, creating business and value.” — Unknown Executive, Executive · 2026-08-13 That shift from treating AI as a cost-saving tool to a potential revenue engine is the core change in this quarter's story.From Efficiency to Monetization: Dr. Da Wei and Beyond
The company has visibly moved the AI needle. During the call, Cao Dong detailed progress on Dr. Da Wei, the AI physician persona, noting its user base grew 4x and that it has begun to replace human consultations for basic informational tasks. This aligns with a broader strategy: “So that's why we are able to lead the market in our pharmaceutical or medication sales.” — Dong Cao, Executive Director and CEO · 2026-08-13 The CEO's confidence stems from a multi-pronged moat—supply chain, fulfillment, and regulatory compliance—that he argued is hard to replicate. The AI commercialization path is still in its early innings. Cao Dong acknowledged, “I cannot say that for sure, but I would say we are halfway through.” — Unknown Executive, Executive · 2026-08-13 He outlined three verticals: user-facing AI (Dr. Da Wei), doctor-facing AI (Zhuoyi), and hospital-facing AI, all of which have already entered early commercial agreements. A notable surprise was the success of the Happy Joyful Weight Losing app, which ranked at the top of new app downloads, demonstrating JD Health's ability to combine niche healthcare management with its ecosystem. This is a meaningful evolution from prior quarters. In the March 2025 call, CEO Jin Enlin had said, “We will further invest in AI, large language models and other innovative technological applications to drive AI-powered transformation across our existing businesses...” — Jin Enlin, Executive Director and Chief Executive Officer (CEO) · 2025-03-07 And in August 2025, he noted, “We have fully deployed AI across existing business.” — Enlin Jin, Executive Director and CEO · 2025-08-14 But now the company is talking about standalone AI businesses, with tangible commercial agreements and a user base that has quadrupled. That is a clear step forward.Regulatory Tailwinds in Nutrition and Supplements
Another notable theme was the regulatory environment for nutrition and supplements. Cao Dong acknowledged short-term headwinds from fake overseas brands and clarified categories, but argued that these measures favor compliant, high-quality players. He framed it as an opportunity: “So for us, who has a robust supply chain and a strong reputation, it positions us in a very good position.” — Dong Cao, Executive Director and CEO · 2026-08-13 This echoes his emphasis on mind share—a recurring keyword in the company's trajectory, indicating that the executives see regulatory scrutiny as a catalyst to consolidate their lead. The company also highlighted its supply chain capability as the bedrock of its competitive advantage, especially in out-of-hospital pharmaceuticals. In a market where online penetration remains low, JD Health's years of investment in logistics, compliance, and professional services appear to be paying off.Outlook and Shareholder Returns
Management expressed confidence in sustaining better-than-industry growth in the second half, despite slower supplement growth. The first-ever share repurchase program—up to USD 1 billion, announced in May—has already seen HKD 840 million worth of shares repurchased and cancelled. CFO Deng Hui noted that the company's cash position remains robust, with RMB 71.5 billion in cash and equivalents, enabling continued buyback execution. In closing, Cao Dong reiterated the path to sustained profitability:Overall, this quarter marks a subtle but important pivot: JD Health is no longer just touting AI as an efficiency tool—it is positioning it as a future revenue stream, backed by real user traction and early commercial agreements. With margins expanding steadily and a clear moat in supply chain and mind share, the company appears well-placed to ride the dual waves of healthcare digitalization and AI adoption in China.We have clear pathways for sustained profitability improvement, cost efficiencies from economies of scale and a stronger supply chain, a more favorable business profile driven by the growth of AI Power Digital Services and continued improvements in operating efficiency.